ADR Biomedical HoldingsADR Biomedical Holdings Inc.3750東証スタンダード情報・通信業FY ending Mar 2026, consolidated, J-GAAP

ADR Biomedical Holdings FY ending Mar 2020 results

About 94% of ADR Biomedical Holdings's sales come from Real Asset, with Medical making up much of the rest.

It lost about ¥11 for every ¥100 of sales at the operating level.

Where the money goes

For every ¥100 ADR Biomedical Holdings sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 64.1% → Operating margin -10.9% → Net margin 27.1%

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第20期(2023/04/01－2024/03/31)
ID S100TUF62024-06-26Open
EDINET (FSA Japan)
有価証券報告書－第18期(令和3年4月1日－令和4年3月31日)
ID S100OEC72022-06-23Open
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年4月1日－令和3年3月31日)
ID S100LPPV2021-06-24Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.